These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 38404083

  • 21. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
    McCarthy M, Francis R, Tang C, Watts J, Campbell A.
    Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448
    [Abstract] [Full Text] [Related]

  • 22. [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.
    Hirmas N, Al-Ibraheem A, Herrmann K, Alsharif A, Muhsin H, Khader J, Al-Daghmin A, Salah S.
    Mol Imaging Biol; 2019 Jun 15; 21(3):574-581. PubMed ID: 30215174
    [Abstract] [Full Text] [Related]

  • 23. An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients.
    Dietlein F, Kobe C, Vázquez SM, Fischer T, Endepols H, Hohberg M, Reifegerst M, Neumaier B, Schomäcker K, Drzezga AE, Dietlein M.
    J Nucl Med; 2022 Apr 15; 63(4):573-583. PubMed ID: 34326129
    [Abstract] [Full Text] [Related]

  • 24. Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens.
    Corona-Montes VE, González-Cuenca E, Fernández-Noyola G, Olarte-Casas MA, Bobadilla-Salazar D, Medrano-Urtecho HM, Asimakopoulos AD.
    Urol Oncol; 2021 Aug 15; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [Abstract] [Full Text] [Related]

  • 25. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers.
    Hope TA, Benz M, Jiang F, Thompson D, Barbato F, Juarez R, Hernandez Pampaloni M, Allen-Auerbach M, Gupta P, Fendler WP, Calais J.
    J Nucl Med; 2023 Nov 15; 64(11):1744-1747. PubMed ID: 37591547
    [Abstract] [Full Text] [Related]

  • 26. Predicting Outcomes of Indeterminate Bone Lesions on 18F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer.
    Phelps TE, Harmon SA, Mena E, Lindenberg L, Shih JH, Citrin DE, Pinto PA, Wood BJ, Dahut WL, Gulley JL, Madan RA, Choyke PL, Turkbey B.
    J Nucl Med; 2023 Mar 15; 64(3):395-401. PubMed ID: 36265908
    [Abstract] [Full Text] [Related]

  • 27. Comparing the role of 99m Tc-HYNIC-PSMA-11 and 99m Tc-MDP scintigraphy for the initial staging of intermediate to high-risk prostate cancer.
    Ghaedian T, Abdinejad M, Nasrollahi H, Ghaedian M, Firuzyar T.
    Nucl Med Commun; 2023 Oct 01; 44(10):864-869. PubMed ID: 37464793
    [Abstract] [Full Text] [Related]

  • 28. Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study).
    Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, Novruzov F, Lengana T, Granados C, Kumar R, Rangarajan V, Al-Ibraheem A, Hourani M, Ali NS, Ahmad A, Keidar Z, Küçük O, Elboga U, Bogoni M, Paez D.
    J Nucl Med; 2022 Feb 01; 63(2):240-247. PubMed ID: 34215674
    [Abstract] [Full Text] [Related]

  • 29. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T.
    Ann Nucl Med; 2019 Oct 01; 33(10):766-775. PubMed ID: 31338731
    [Abstract] [Full Text] [Related]

  • 30. 68Ga-PSMA PET/CT for the evaluation of metastasis in patients with prostate cancer: A systematic review and meta-analysis.
    Zhou J, Wu R, Wang W, Zhao Y, Liu X.
    Hell J Nucl Med; 2022 Oct 01; 25(3):297-311. PubMed ID: 36576728
    [Abstract] [Full Text] [Related]

  • 31. A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the bone lesion detection of conventional imaging and 18F-PSMA-PET/CT.
    Bodar YJL, Luining WI, Keizer B, Meijer D, Vellekoop A, Schaaf M, Hendrikse NH, Van Moorselaar RJA, Oprea-Lager DE, Vis AN.
    Urol Oncol; 2023 Apr 01; 41(4):205.e17-205.e24. PubMed ID: 36588019
    [Abstract] [Full Text] [Related]

  • 32. 18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.
    De Man K, Van Laeken N, Schelfhout V, Fendler WP, Lambert B, Kersemans K, Piron S, Lumen N, Decaestecker K, Fonteyne V, Delrue L, De Vos F, Ost P.
    Eur Urol; 2022 Nov 01; 82(5):501-509. PubMed ID: 35690515
    [Abstract] [Full Text] [Related]

  • 33. Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.
    Janssen JC, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR.
    Eur Radiol; 2018 Feb 01; 28(2):610-619. PubMed ID: 28779400
    [Abstract] [Full Text] [Related]

  • 34. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer.
    Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, Tamaki N, Schwaiger M, Maurer T, Eiber M.
    Eur J Nucl Med Mol Imaging; 2016 Nov 01; 43(12):2114-2121. PubMed ID: 27290607
    [Abstract] [Full Text] [Related]

  • 35. Should 68Ga-PSMA PET/CT Replace CT and Bone Scan in Clinical Staging of High-risk Prostate Cancer?
    Pepe P, Pennisi M.
    Anticancer Res; 2022 Mar 01; 42(3):1495-1498. PubMed ID: 35220244
    [Abstract] [Full Text] [Related]

  • 36. Potential role of 68Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study.
    Aggarwal P, Singh H, Das CK, Mavuduru RS, Kakkar N, Lal A, Gorsi U, Kumar R, Mittal BR.
    Eur J Radiol; 2024 Jan 01; 170():111218. PubMed ID: 38007857
    [Abstract] [Full Text] [Related]

  • 37. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).
    Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ.
    Eur Urol Oncol; 2021 Aug 01; 4(4):635-644. PubMed ID: 32675047
    [Abstract] [Full Text] [Related]

  • 38. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 01; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 39. Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer.
    Rosar F, Khreish F, Marlowe RJ, Schaefer-Schuler A, Burgard C, Maus S, Petto S, Bartholomä M, Ezziddin S.
    Eur J Nucl Med Mol Imaging; 2023 Jul 01; 50(9):2899-2909. PubMed ID: 37148297
    [Abstract] [Full Text] [Related]

  • 40. 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy.
    Esen T, Falay O, Tarim K, Armutlu A, Koseoglu E, Kilic M, Seymen H, Sarikaya AF, Kiremit MC, Balbay MD, Canda AE, Baydar DE, Kordan Y, Demirkol MO, Tilki D.
    Eur Urol Focus; 2021 Mar 01; 7(2):288-293. PubMed ID: 33509671
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.